AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01483625 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tiotropium
Description: 18mcg
Study NCT01483625 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo
Study NCT03099824 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GC4711 Oral Capsule G-101
Description: 164 mg (2 capsules)
Study NCT03099824 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GC4711 Oral Capsule G-101
Description: 246 mg (3 capsules)
Study NCT03099824 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GC4711 Oral Capsule G-111
Description: 175 mg (1 capsule)
Study NCT03099824 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GC4711 Oral Capsule G-112
Description: 145 mg (1 capsule)
Study NCT03099824 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GC4711 Oral Capsule G-119
Description: 233 mg (1 capsule)
Study NCT03099824 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GC4711 Oral Capsule G-125
Description: 233 mg (1 capsule)
Study NCT03099824 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV GC4711
Description: GC4711 will be infused IV as a single dose of 30 mg in 250 mL normal saline, totaling 251 mL, over a 60-minute period using a programmable pump.
Study NCT01133236 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Salt and fluid restriction
Description: I: Intervention Prescription of low-sodium diet with additional 2 g of sodium and water restriction to 800 mL/day.~II: Control Prescription without sodium and fluid restriction.
Study NCT03537651 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TEZ/IVA
Description: Fixed-dose combination tablet for oral administration.
Study NCT03537651 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IVA
Description: Tablet for oral administration.
Study NCT04619303 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone intravitreal implant
Description: Intravitreal injection of 0.7mg dexamethasone implant
Study NCT04619303 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab Injectable Product
Description: Invtravitreal injection of 1.25mg/0.05mL bevacizumab
Study NCT05527236 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Breathing Exercise
Description: The research was carried out in two stages. In the first stage, for the experimental groups at the 36th-39th weeks of pregnancy, a 10-minute breathing exercise was performed 3 times a week using virtual reality glasses and a breathing exercise device. In the second stage of the study (when the cervical dilatation was 4 cm), the breathing exercise group was made breathing exercises again. As soon as the virtual reality glasses and breathing exercise device were removed, VAS was applied. In order to evaluate the second and third stages of labor, the birth evaluation section of the labor observation form was filled out. Satisfaction with birth was evaluated with the ''Birth Satisfaction Scale'' within the first 4 hours after birth after the delivery was completed.
Study NCT05527236 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual Reality
Description: The research was carried out in two stages. In the first stage, for the experimental groups at the 36th-39th weeks of pregnancy, a 10-minute breathing exercise was performed 3 times a week using virtual reality glasses and a breathing exercise device. In the second stage of the study (when the cervical dilatation was 4 cm) the virtual reality group watched a 10-minute video with virtual reality glasses. Once the virtual reality glasses were removed from experimental groups Visual Analogue Scale was applied. Birth satisfaction was evaluated with the Birth Satisfaction Scale within the first 4 hours after the delivery was completed.
Study NCT06112717 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Supportive-Educative Nursing Care
Description: Adolescents in the intervention group were received Supportive-Educative Nursing Care based on Orem's Self Care Deficit Nursing Theory
Study NCT01186848 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Combination treatment
Description: The contralateral side received the combination of micro-focused ultrasound treatment and 1550nm-fractionated laser alternatively every 2 weeks for a total of 4 treatments with site-match control area of baseline striae on each side.
Study NCT01186848 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 1550-nm erbium-doped fractionated laser
Description: Each side of thigh (or abdomen) was randomized to receive 1550nm-fractionated laser treatment every 2 weeks for a total of 4 treatments on one side.
Study NCT03966794 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Epidural Electrical Stimulation
Description: Participants had finished the previous clinical trial with functional neural regeneration collagen scaffold transplantation, and will receive epidural electrical stimulation of the spinal cord in this group.
Study NCT03966794 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Functional scaffold & Epidural Electrical Stimulation
Description: Participants with acute complete SCI or chronic complete SCI will receive functional neural regeneration scaffold transplantation and epidural electrical stimulation of the spinal cord.
Study NCT03203356 — intervention group
Intervention type: DRUG
Intervention: growth hormone
Description: Children with a diagnosis of GHD will practice GH replacement therapy in line with normal clinical practice and international guidelines. Controls will be evaluated just at baseline.
Study NCT00208507 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 28 mm ceramic head on ceramic acetabular liner.
Description: Total hip replacement with 28 mm ceramic head on ceramic liner articulation
Study NCT00208507 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 28 mm ceramic head on polyethylene liner
Description: Total hip replacement with 28 mm ceramic head on a polyethylene liner articulation.
Study NCT03707678 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2245035
Description: GSK2245035 will be administered weekly once as a nasal spray solution with dosing strength of 10 ng per actuation. GSK2245035 will be available as a saline formulation, preserved with benzalkonium chloride and disodium edetate in an amber glass bottle fitted with a screw-fit atomizing pump.
Study NCT03707678 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered weekly once as a nasal spray solution. Placebo will be available as a saline formulation, preserved with benzalkonium chloride and disodium edetate in an amber glass bottle fitted with a screw-fit atomizing pump.
Study NCT03707678 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FP-DPI
Description: FP will be administered using Diskus inhaler with dosing strengths of 500, 250, 100, 50 µg twice daily per actuation.
Study NCT00004635 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Patients will receive the placebo if they initially received thalidomide. The starting dose of placebo 200 mg (four capsules of 100-50 mg capsules) orally once daily at bedtime.
Study NCT03650556 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TactiCath™ Contact Force Ablation Catheter, Sensor Enabled™
Description: Ablation procedure for Persistent AF
Study NCT00398918 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: zonisamide
Description: zonisamide (100 mg)one time
Study NCT00398918 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Comparator
Study NCT00723580 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: risperidone
Description: Five treatment conditions: 1. Baseline no medication 2. Risperidone .25 mg at bedtime (q.h.s.) x 7 days 3. Risperidone .25 mg twice daily (b.i.d.) 4. Risperidone .25 mg three times a day (t.i.d.) and 5. Risperidone .5 mg three times a day (t.i.d.).
Study NCT02037022 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pivotal Response Treatment Package (PRT-P)
Study NCT02125968 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: interactive video game
Description: short- and medium-term therapeutic effects
Study NCT02125968 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: therapeutic exercise
Description: short- and medium-term therapeutic effects
Study NCT03421535 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sleeper Stretch
Description: Internal Range of motion of dominant shoulder
Study NCT03421535 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Opposite SI joint Stretch
Description: Internal range of motion of dominant shoulder
Study NCT02122458 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: mild-gain hearing aids with high-frequency emphasis over 6-months
Description: open-fit hearing aids with mild amplification in the high frequencies.
Study NCT03707678 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: FP-DPI
Description: FP will be administered using Diskus inhaler with dosing strengths of 500, 250, 100, 50 µg twice daily per actuation.
Study NCT03707678 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albuterol/Salbutamol
Description: Albuterol/Salbutamol MDI will be administered for symptom relief from screening to the end of the study.
Study NCT03707678 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Albuterol/Salbutamol
Description: Albuterol/Salbutamol MDI will be administered for symptom relief from screening to the end of the study.
Study NCT03707678 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: eDairy
Description: Subjects will record all the alerts indicative of worsening of asthma in eDairy.
Study NCT02764632 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Digital facilitation
Study NCT02046031 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ginkgolides Meglumine Injection
Description: 25 mg, ivdrip, once.
Study NCT02029404 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Tibial nerve group
Description: After the recovery of the sensitivity we will start the continuous infusion of levobupivacaine 0,125% with a portable pump (Mini Rythmic Evolution, Micrel Medical Devices) with a flow basal rate 2 ml/h and a rescue bolus doses of 2 ml (lock out 20 minutes). Before the discharge from the hospital, if the NRS will be > 4, a bolus of 10 ml of Mepivacaine 1% through the catheter could be administered.~An information sheet will be released at the discharge and the medical indication for any rescue doses at home.~The patients will be contacted by phone at POD 1-2 and will allowed to answer to a questionnaire (see endpoint) At POD 3 the patients will come in our ambulatory where we will remove the catheter and they will return the pump
Study NCT02029404 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Tibial peroneal nerve group
Description: After the recovery of the sensitivity we will start the continuous infusion of levobupivacaine 0,125% with a portable pump (Mini Rythmic Evolution ,Micrel Medical Devices )with a flow basal rate 2 ml/h and a rescue bolus doses of 2 ml (lock out 20 minutes). Before the discharge from the hospital, if the NRS will be > 4, a bolus of 10 ml of Mepivacaine 1% through the catheter could be administered.~An information sheet will be released at the discharge and the medical indication for any rescue doses at home.~The patients will be contacted by phone at POD 1-2 and will allowed to answer to a questionnaire (see endpoint) At POD 3 the patients will come in our ambulatory where we will remove the catheter and they will return the pump
Study NCT04065477 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: computer-based cognitive rehabilitation (CBCR)
Description: Program designed to improve strategic cognitive domains (e.g., complex attention, working memory)
Study NCT02404155 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clozapine
Study NCT01815892 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Withdrawal of furosemide
Description: The patient (previously on furosemide) will have the furosemide stopped for 2 weeks. The interdialytic weight gain, BP and 24 hour urine volume and sodium excretion will be measured
Study NCT01815892 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: furosemide administration
Description: The patient will receive 120 mgm furosemide daily for 2 weeks and the interdialytic weight gain, BP and 24 hr urine volume and sodium excretion will be measured.
Study NCT03246880 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tadalafil 5mg
Description: per oral for 12weeks after 2\~4weeks run-in period
Study NCT03246880 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tadalafil 5mg
Description: per oral for 12weeks after 2\~4weeks run-in period
Study NCT02766855 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cysteamine
Description: Patients were asked to use topical cysteamine 0.55% eye drops every 2 hours while awake to both eyes.
Study NCT03109457 — intervention group
Intervention type: OTHER
Intervention: oral squamous cell carcinoma
Description: Histological diagnosis of H\&E stained sections will be performed according to WHO guidelines by 2 independent pathologists.
Study NCT03483701 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Remediation Therapy
Description: The intervention of interest for participants in the experimental group is the addition of up to 5 hours per week of computerized cognitive exercises. Cognitive training can be done at home on a computer. For participants without access to a computer, a laptop/tablet computer with the necessary software will be provided for the duration of training. Participants will be able to complete the cognitive exercises on their own schedule, with participation verified by the software. Participants will also receive 1 hour/week of individual coaching to discuss cognitive remediation progress, e.g. to learn about different cognitive domains and develop ways to generalize their cognitive remediation gains.
Study NCT02006511 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Incisional Neg Pressure Wound Therapy (Prevena™)
Description: Negative pressure wound therapy dressing applied over closed surgical incision
Study NCT02006511 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care wound therapy
Description: Gauze type dressing.
Study NCT01788488 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Use of procalcitonin as biomarker to guide therapy
Study NCT02432742 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Restylane Perlane
Description: Intradermal injection
Study NCT02432742 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Restylane
Description: Intradermal injection
Study NCT03707678 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: eDairy
Description: Subjects will record all the alerts indicative of worsening of asthma in eDairy.
Study NCT03707678 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ACQ-6
Description: ACQ-6 will include six questions which enquire about the frequency and/or severity of symptoms. The response options for all these questions consist of a zero (no impairment/limitation) to six (total impairment/limitation) scale.
Study NCT03707678 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: ACQ-6
Description: ACQ-6 will include six questions which enquire about the frequency and/or severity of symptoms. The response options for all these questions consist of a zero (no impairment/limitation) to six (total impairment/limitation) scale.
Study NCT00440414 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib (Tarceva)
Description: Erlotinib at the dose of 150 mg orally once a day continually until progression
Study NCT00440414 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed (Alimta)
Description: Pemetrexed at the dose of 500mg/m2 IV infusion every 3 weeks for 6 consecutive cycles
Study NCT04234607 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQB2450
Description: TQB2450 is a humanized monoclonal antibody targeting programmed death ligand-1 (PD-L1), which prevents PD-L1 from binding to PD-1 and B7.1 receptors on T cell surface, restores T cell activity, thus enhancing immune response and has potential to treat various types of tumors.
Study NCT01814644 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TRIMM Intervention
Description: Individuals in the TRIMM arm receive daily, individualized text-messages promoting positive lifestyle changes to support weight loss/management.
Study NCT01814644 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care
Description: Individual assessment, lifestyle counseling
Study NCT04234607 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib
Description: a multi-target receptor tyrosine kinase inhibitor
Study NCT04234607 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Etoposide is a cell cycle-specific antitumor drug
Study NCT04234607 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etoposide
Description: Etoposide is a cell cycle-specific antitumor drug
Study NCT04234607 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin is cell cycle nonspecific antitumor drug
Study NCT00857142 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxymorphone hydrochloride
Study NCT00857142 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Opana
Study NCT04234607 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Carboplatin is cell cycle nonspecific antitumor drug
Study NCT04234607 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQB2450（blank）
Description: Subjects administrated TQB2450 (blank) intravenously (IV) on Day 1 of each 21-day
Study NCT04234607 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TQB2450（blank）
Description: Subjects administrated TQB2450 (blank) intravenously (IV) on Day 1 of each 21-day
Study NCT04234607 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anlotinib（blank)
Description: Subjects administrated anlotinib (blank) in fasting conditions, once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21)
Study NCT03913988 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Lucid Dream
Description: Lucid dream techniques are a set of strategies to induce the ability to obtain conscious awareness during the dream state and include mental suggestions before sleep.
Study NCT00635895 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Manual Lymph Drainage Therapy and Connective Tissue Massage
Description: The treatment program was carried out five times a week, during a 3-week period for both Manual Lymph Drainage Therapy and Connective Tissue Massage groups
Study NCT03913988 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Stress Reduction
Description: Stress reduction techniques are a set of strategies designed to reduce anxiety and include meditation and guided imagery.
Study NCT03913988 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Sleep Hygiene Techniques
Description: Sleep hygiene is a set of techniques intended to enhance sleep quality and quantity and include maintaining consistent sleep-wake times and avoiding stimulating activities before bed.
Study NCT04477889 — intervention group
Intervention type: OTHER
Intervention: Treatment for COVID-19
Description: Patients treated for COVID-19
Study NCT02559258 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.1 mg/kg epsi-gam or placebo (6:2)
Description: administered as a single intravenous infusion on Day 1, infused over 30 minutes
Study NCT00943137 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil
Description: Chemotherapy will be one of the following:~1. de Gramont: folinic acid 400mg/m2 day 1, 5-FU 400 mg/m2 bolus on day 1 followed by 46 hour continuous infusion of 5-FU 2400mg/m2.~2. FOLFIRI: Irinotecan 180mg/m2 on day 1, folinic acid 400mg/m2 day 1, 5-FU 400 mg/m2 bolus on day 1 followed by 46 hour continuous infusion of 5-FU 2400mg/m2.~3. Modified FOLFOX-6: Oxaliplatin 85mg/m2 on day 1, folinic acid 400mg/m2 day 1, 5-FU 400 mg/m2 bolus on day 1 followed by 46 hour continuous infusion of 5-FU 2400mg/m2.
Study NCT04252079 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Endovascular Repair of Juxtarenal Aortic Aneurysm
Description: 1. History taking and clinical examination.~2. Preoperative Imaging~   CTA is the cross-sectional imaging modality of choice.~3. Preoperative evaluation~   a-Renal evaluation~   b_ cardiac evaluation C-Pulmonary evaluation~4. Surgical techniques~   1. Anesthesia The use of general anesthesia due to the duration of the procedures and the necessity to control patient breathing to allow precise imaging and accurate device deployment.~  2. Intra operative imaging A hybrid operating room with high-quality fixed imaging is needed for the performance of FEVAR.~C-Device delivery and deployment all FEVAR procedures begin with access of the femoral arteries by either open or percutaneous technique.
Study NCT00661856 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Soy protein
Description: 25g of Soy protein with or with out 90mg of isoflavones ones a day given for a period of 24 months
Study NCT00661856 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Soy protein
Description: 25g of Soy protein with or with out 90mg of isoflavones ones a day given for a period of 24 months